Morgan Stanley
ALXN

Morgan Stanley’s Alexion Pharmaceuticals ALXN Stock Holding History

Morgan Stanley’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,725,693
Closed -$317M – 8258
2021
Q2 		$317M Sell
1,725,693
-74,500
-4% -$12.8M 0.04% 389
2021
Q1 		$275M Buy
1,800,193
+674,309
+60% +$104M 0.04% 386
2020
Q4 		$176M Buy
1,125,884
+479,034
+74% +$61.6M 0.03% 518
2020
Q3 		$74M Buy
646,850
+122,918
+23% +$13.3M 0.01% 723
2020
Q2 		$58.8M Sell
523,932
-106,745
-17% -$11.3M 0.01% 764
2020
Q1 		$56.6M Sell
630,677
-357,176
-36% -$35.1M 0.02% 686
2019
Q4 		$107M Buy
987,853
+406,580
+70% +$43.5M 0.02% 579
2019
Q3 		$56.9M Sell
581,273
-62,573
-10% -$7.05M 0.02% 787
2019
Q2 		$84.3M Buy
643,846
+43,783
+7% +$5.64M 0.02% 617
2019
Q1 		$81.1M Sell
600,063
-189,884
-24% -$23.6M 0.02% 616
2018
Q4 		$76.9M Buy
789,947
+8,056
+1% +$952K 0.02% 634
2018
Q3 		$109M Buy
781,891
+16,017
+2% +$2.01M 0.03% 566
2018
Q2 		$95.1M Sell
765,874
-249,058
-25% -$29.1M 0.03% 597
2018
Q1 		$113M Buy
1,014,932
+274,605
+37% +$32.8M 0.03% 528
2017
Q4 		$88.5M Sell
740,327
-176,211
-19% -$21.5M 0.02% 645
2017
Q3 		$129M Buy
916,538
+131,315
+17% +$17.8M 0.04% 457
2017
Q2 		$95.5M Buy
785,223
+199,741
+34% +$23.2M 0.03% 576
2017
Q1 		$71M Buy
585,482
+309,299
+112% +$39.9M 0.02% 727
2016
Q4 		$33.8M Sell
276,183
-178,327
-39% -$21.8M 0.01% 1115
2016
Q3 		$55.7M Sell
454,510
-226,032
-33% -$29.1M 0.02% 788
2016
Q2 		$79.5M Buy
680,542
+533,863
+364% +$75.7M 0.03% 582
2016
Q1 		$20.4M Sell
146,679
-128,479
-47% -$18.9M 0.01% 1295
2015
Q4 		$52.5M Sell
275,158
-398,220
-59% -$69.6M 0.02% 759
2015
Q3 		$105M Buy
673,378
+235,205
+54% +$42.9M 0.04% 452
2015
Q2 		$79.2M Sell
438,173
-205,538
-32% -$35.5M 0.03% 618
2015
Q1 		$112M Sell
643,711
-262,493
-29% -$47.5M 0.04% 470
2014
Q4 		$168M Buy
906,204
+182,600
+25% +$33.8M 0.06% 341
2014
Q3 		$120M Sell
723,604
-83,635
-10% -$13.7M 0.05% 443
2014
Q2 		$126M Buy
807,239
+90,238
+13% +$14.2M 0.05% 426
2014
Q1 		$109M Buy
717,001
+349,555
+95% +$55.6M 0.05% 448
2013
Q4 		$48.8M Buy
367,446
+123,498
+51% +$14.8M 0.02% 747
2013
Q3 		$28.3M Sell
243,948
-55,060
-18% -$6.04M 0.01% 985
2013
Q2 		$27.6M Buy
+299,008
New +$28.8M 0.01% 960

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Morgan Stanley's ALXN Position: Q3 2021 in Review

Morgan Stanley sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,725,693 shares — an estimated $317M sold.

Morgan Stanley first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $317M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Morgan Stanley reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Morgan Stanley sold 1,725,693 Alexion Pharmaceuticals shares in Q3 2021, an estimated $317M.
  • Morgan Stanley first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Morgan Stanley's Alexion Pharmaceuticals position peaked at $317M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Morgan Stanley's 13F filing for Q3 2021, filed 15 Nov 2021.